Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) said Monday it completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market.
The deal, first announced in June, gives Aspire 100% ownership of Dura Driver Control Systems, or DCS, which is now a wholly owned subsidiary. Aspire paid about $30 million in cash.
DCS is a tier-one automotive supplier focused on electronic driver controls and systems supporting vehicle electrification, safety, lightweighting and sustainability. Aspire said the acquisition is expected to add revenue, earnings and cash flow while diversifying its business.
Aspire Secures $22.5 Million Credit Facility
The company also entered into a $22.5 million senior secured revolving credit facility in connection with the transaction. The company said it will use borrowings from the facility, along with cash on hand, to finance the acquisition.
“Closing the DCS acquisition is a cash-flow-positive milestone that structurally enhances Aspire’s valuation,” CEO and Board Chair Kraig Higginson said.
Higginson said DCS’ financial profile immediately gives Aspire greater scale and adds high-volume revenue streams.
RBW Capital Partners LLC is serving as Aspire’s exclusive financial advisor for the acquisition. Securities and brokerage services are offered through Dawson James Securities Inc.
DCS Brings More Than $200 Million In Annual Revenue
DCS generated $209.5 million in audited revenue and $22.3 million in adjusted EBITDA in 2025. For the first six months of 2026, the company generated unaudited revenue of about $103.9 million and adjusted EBITDA of $10.5 million.
DCS operates 11 manufacturing facilities across North America, Europe and Asia. It has more than 50 customers and supports more than 150 vehicle platforms and 250 high-volume global vehicle models. Its portfolio includes more than 275 distinct parts and over 310 patents.
DCS CEO Hans Vorstenbosch will remain CEO of the subsidiary, working with the existing management team under the leadership of Lakewood & Company Chairman Gregory J. Corona.
Before the acquisition, Aspire’s core business centered on a patent-pending sublingual drug-delivery technology designed to deliver active ingredients directly into the bloodstream while bypassing the gastrointestinal tract.
ASBP Stock Price Activity: Aspire Biopharma Holdings shares were down 0.39% at $7.70 during premarket trading on Monday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments